Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation (Astronef)
Impact of the Absence of Steroids on the Evolution of Renal Function and on the Progression of Graft Fibrosis, Quantified by Numerical Method, in Patients With Renal Transplant
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69437
- CHU de Lyon
-
Nantes, France, 44093
- Nantes university hospital
-
Nice, France, 06000
- Chu De Nice
-
Paris, France, 75743
- AP-HP - Hôpital Necker
-
Paris, France, 94275
- AP-HP - Hôpital Bicêtre
-
Saint-Etienne, France, 42270
- CHU de Saint-Etienne
-
Toulouse, France, 31049
- CHU de Toulouse
-
Tours, France, 37044
- CHRU de Tours
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Pre-Inclusion Criteria:
- Adults aged 18 to70 years,
- Accepting to give, after information, their signed informed consent form,
- Not having difficulties to understand and communicate with the investigator and his representatives,
- Requiring a renal transplant [first or second transplant (except if the first renal transplant was lost due to rejection)],
- Patient insured.
Inclusion criteria :
- Transplant of a kidney from a deceased or living donor (non HLA-identical) with ABO compatibility,
- Existence of a renal graft biopsy (or of one of the grafts, if bi-renal transplant) before transplantation,
- Percentage of positive responses to PRA (panel reactive antibodies), measured by the Luminex® less than 20% of IgG anti-T or absence of positive DSA by Luminex regardless of the mean fluorescence (MFI) within the last 6 months,
- Negative cross match T in cytotoxicity and / or flow cytometry,
- Negative pregnancy test for patients of childbearing age, and consent to use an effective contraception throughout the study and 6 weeks after the end of the study.
Exclusion Criteria:
- First renal transplant lost due to rejection,
- Combined transplantation,
- Previous history of transplantation other than kidney,
- Non beating donor heart,
- Presence of positive DSA by Luminex® regardless of the average of fluorescence (MFI),
- Patients receiving corticosteroids at the time of transplantation,
- Necessity to continue administration of systemic immunosuppressive treatment before transplantation,
- Infections or severe diarrhea, vomiting, upper gastrointestinal tract malabsorption or active peptic ulcers, concomitant, significant and uncontrolled,
- Subject or HIV positive donor,
- Replicating viral hepatitis at the time of randomization,
- Known allergy or intolerance to tacrolimus, macrolide, corticosteroids, mycophenolate mofetil or to any of the excipients,
- Diagnosis of de novo malignancy prior to transplantation, with the exception of treated effectively basal cell or squamous cell carcinomas of the skin,- Current participation at another clinical study,
- All clinical condition that the investigator considers incompatible with the conduct of the study in acceptable security conditions,
- Inability of patient to comply with study procedures,
- Pregnant or breast-feeding women,
- Person placed under guardianship, under protection of law.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Absence of corticotherapy post-transplantation
All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) without corticotherapy post-transplantation.
|
No study treatment
|
|
Active Comparator: Corticotherapy post-transplantation
All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) with corticotherapy post-transplantation : prednisone or prednisolone orally for at least one year post-transplantation.
|
Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of fibrosis of the graft
Time Frame: One year post-transplantation
|
Evolution of the percentage of fibrosis of the graft during the first year after transplantation (pre-transplant biopsy versus biopsy at one year), by numerical reading of fibrosis by image analysis.
|
One year post-transplantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of fibrosis of the graft
Time Frame: One year post-transplantation
|
Evolution of the percentage of fibrosis of the graft during the first year after transplantation (pre-transplant biopsy versus biopsy at one year of which the blinded readings to treatment group are made by two independent anatomical pathologists, the Banff criteria 2009).
|
One year post-transplantation
|
|
Percentage of fibrosis of the graft.
Time Frame: One year post-transplantation
|
The percentage of fibrosis of the graft at one year post-transplantation (biopsy at one year with numerical reading of fibrosis by image analysis and blinded reading to treatment group by two independent anatomical pathologists, the Banff criteria 2009).
|
One year post-transplantation
|
|
Average glomerular filtration rate
Time Frame: One year post-transplantation
|
The average glomerular filtration rate, calculated by the MDRD formula (four variables, Modification Diet in Renal Disease).
|
One year post-transplantation
|
|
Dialysis session
Time Frame: One year post-transplantation
|
The percentage of patients with at least one dialysis session realised during the first year of transplant.
|
One year post-transplantation
|
|
Ratio of proteinuria/creatinuria
Time Frame: One year post-transplantation
|
Average of ratio of proteinuria/creatininuria (mg / mmol).
|
One year post-transplantation
|
|
Episode of acute rejection
Time Frame: One year post-transplantation
|
The percentage of patients with at least one episode of acute rejection during the first year after transplantation.
We will distinguish biopsy-proven acute rejection (RABP), the corticosteroids resistant RABP and severe RABP (Banff 2009).
|
One year post-transplantation
|
|
Diagnosis of DSA
Time Frame: One year post-transplantation
|
The percentage of patients with a diagnosis of DSA (Luminex® method) at 3 months and 1 year post-transplantation.
|
One year post-transplantation
|
|
Percentage of graft failure
Time Frame: One year post-transplantation
|
The percentage of graft failure (death or return to dialysis) during the first year of transplantation (the short duration of the study avoids the management of right censoring).
|
One year post-transplantation
|
|
Difference between numerical reading of fibrosis and evaluation by anatomical pathologists
Time Frame: One year post-transplantation
|
The difference between the percentage of graft fibrosis evaluated by numerical reading of fibrosis and that assessed by two independent anatomical pathologists (Banff 2009 criteria) at baseline, 3 months and 1 year post-transplantation.
|
One year post-transplantation
|
|
Number of adverse events
Time Frame: One year post-transplantation
|
Adverse events (AE) at 12 months post-transplantation, of which AEs of special interest (NODAT, dyslipidemia, hypertension, CMV viral infections, BKV) with an assessment of vital signs, physical examinations and laboratory tests.
|
One year post-transplantation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Diego CANTAROVICH, MD, PhD, CHU de Nantes
- Study Chair: Lionel ROSTAING, Profesor, University Hospital, Toulouse
- Study Chair: Christophe LEGENDRE, Profesor, Hôpital Necker (AP-HP)
- Study Chair: Emmanuel MORELON, Profesor, CHU de Lyon
- Study Chair: Elisabeth CASSUTO-VIGUIER, Doctor, Centre Hospitalier Universitaire De Nice
- Study Chair: Christophe MARIAT, Profesor, CHU de Saint-Etienne
- Study Chair: Matthias BÜCHLER, Profesor, CHRU de Tours
- Study Chair: Antoine DURRBACH, Profesor, Hôpital Bicêtre (AP-HP)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RC11_0013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.